Severe Sepsis Clinical Trial
Official title:
A Multi-centre, Randomised Controlled Trial of Early Goal-directed Therapy in Patients Presenting to the Emergency Department With Severe Sepsis in Australasia
The ARISE RCT is a multi-centre, randomised, controlled trial of EGDT compared to standard
care in patients with severe sepsis presenting to the ED. The study will be conducted in
multiple sites with 1600 patients enrolled into the study.
Hypothesis to be tested: EGDT, compared to standard Australasian resuscitation practice,
reduces 90-day all-cause mortality in patients presenting to the ED with severe sepsis.
The primary aim of the study is to determine whether providing EGDT, compared to standard
care, reduces 90-day mortality in patients presenting to the ED of hospitals in Australasia
with severe sepsis.
Each patient meeting all of the exclusion criteria and none of the exclusion criteria will
be randomised in the ED to receive either EGDT for a total of 6 hours post-randomisation, or
standard care.
Patients assigned to receive EGDT will be cared for by the dedicated ARISE study team. The
patient will receive treatment as per the study protocol for 6 hours with central blood
oxygen levels as the target end-point, then receive standard care.
Patients assigned to receive standard care will continue to be cared for by the hospital
team in accordance with current best practice.
Patients in both groups will also receive any additional treatment needed, such as
antibiotics or surgery.
This study will involve 1600 patients with severe sepsis admitted to the ED from multiple
hospitals.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04804306 -
Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
|
||
| Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
| Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
| Recruiting |
NCT02899143 -
Short-course Antimicrobial Therapy in Sepsis
|
Phase 2 | |
| Completed |
NCT02539147 -
Characterization of Non-canonical Way in Inflammasome Monocytes of Patients With Severe Sepsis
|
N/A | |
| Completed |
NCT01932814 -
Acute Kidney Injury in Septic Critically Ill Patients : Are Aminoglycosides Really Harmful?
|
N/A | |
| Completed |
NCT01929772 -
German Lactat Clearance in Severe Sepsis
|
N/A | |
| Completed |
NCT01449721 -
Preemptive Resuscitation for Eradication of Septic Shock
|
N/A | |
| Active, not recruiting |
NCT01162109 -
Zinc Therapy in Critical Illness
|
Phase 1 | |
| Not yet recruiting |
NCT01211899 -
4G/5G Polymorphism of Plasminogen Activator Inhibitor-1 Gene and Disseminated Intravascular Coagulation in Severe Sepsis and Septic Shock
|
N/A | |
| Completed |
NCT00934011 -
Use of Inflammatory Biomarkers to Guide Antibiotic Therapy in Patients With Severe Infections
|
N/A | |
| Recruiting |
NCT00335907 -
Protocol-driven Hemodynamic Support for Patients With Septic Shock
|
N/A | |
| Completed |
NCT00463645 -
Investigation of Correlation Between Interstitial and Arterial Blood Glucose Concentrations in Septic Patients
|
N/A | |
| Completed |
NCT02361528 -
GM-CSF to Decrease ICU Acquired Infections
|
Phase 3 | |
| Completed |
NCT02734550 -
(1,3)-β-D-glucan Based Diagnosis of Invasive Candida Infection in Sepsis
|
N/A | |
| Completed |
NCT02973243 -
The Vital Signs to Identify, Target, and Assess Level (VITAL) Care Study III
|
N/A | |
| Terminated |
NCT03895853 -
Early Metabolic Resuscitation for Septic Shock
|
Phase 2 | |
| Completed |
NCT01945983 -
Early Use of Norepinephrine in Septic Shock Resuscitation
|
N/A | |
| Completed |
NCT01598831 -
Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy
|
Phase 3 | |
| Enrolling by invitation |
NCT02258984 -
Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial
|
N/A |